Becky Carlyle is funded by leading dementia research charity to start her own group.

We are delighted to announce that Wade-Martins Group Senior Postdoctoral Researcher Dr. Becky Carlyle has been awarded £420K by Alzheimer's Research UK to establish her own group.

Dementia affects nearly a million people in the United Kingdom, with Alzheimer's disease being the most common cause. The accumulation and spread of amyloid protein in the brain is a defining feature of Alzheimer's disease. Researchers believe that this protein sets off a chain of events that leads to nerve cell loss and dementia symptoms. 

With the new £420K funding, Dr. Becky Carlyle and her team will be able to investigate ways to improve resilience to Alzheimer's. They hope to reveal potential targets for new drugs that could help slow the progression of the disease by identifying the proteins that are most important for protecting nerve cells from amyloid damage and a second critical protein called tau.

About her new funding, Dr. Carlyle said “Thanks to this new funding, we will be closer to understanding a key feature of Alzheimer’s, designing treatments to increase resilience in those at risk, and helping limit the impact of this devastating disease.”

Since April 2021, Oxford University's KAVLI Institute for Nanoscience Discovery is proudly serving as a hub for research groups from seven different departments spanning both the medical and physical sciences, including Professor Richard Wade-Martins from the Department of Physiology, Anatomy and Genetics.